|
Reconciliation of Non-GAAP Adjusted EPS Guidance |
Guidance |
||||||||||||||||||||||||
|
Q2 2023 |
Full Year 2023 |
||||||||||||||||||||||||
|
(unaudited) |
Per Share |
Per Share |
|||||||||||||||||||||||
|
GAAP diluted earnings per share guidance |
$1.30 – $1.70 |
$7.75 – $8.75 |
|||||||||||||||||||||||
|
Estimated adjustments |
|||||||||||||||||||||||||
|
Other (a) |
$ — |
$ — |
|||||||||||||||||||||||
|
Adjusted diluted earnings per share guidance |
$1.30 – $1.70 |
$7.75 – $8.75 |
|||||||||||||||||||||||
FDA Greenlights Daiichi Sankyo’s Blood Cancer Drug, A Promising Competitor to Novartis’ Rydapt
The FDA has approved Daiichi Sankyo's (OTC: DSNKY) Vanflyta (quizartinib) in
